Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non–muscle invasive bladder cancer

Autor: Rossana Critelli, H. Barton Grossman, Tilman Todenhöfer, Wassim Kassouf, Bas W.G. van Rhijn, Molly A. Ingersoll, John A. Taylor, Antonia Vlahou, Marta Sanchez-Carbayo, Joan Palou, Mĺiss A. Hudson, Ashish Chandra, Thomas Behrens, Ashish M. Kamat, Bernd J. Schmitz-Dräger, Beate Pesch
Přispěvatelé: urology 24, Schön Klinik Nürnberg/Fürth, Urologische Universitätsklinik, Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen, Division of Surgical Oncology (Urology), Antoni van Leeuwenhoek Hospital - The Netherlands Cancer Institute, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Department of Cardiology Ochsner Clinic Foundation, Cellular pathology, St Thomas' Hospital [London], Immunobiologie des Cellules Dendritiques, Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), McGill University Health Center [Montreal] (MUHC), servicio de urologia, Fundación Puigvert, Division of urology, University of Connecticut (UCONN), Biomedical Research Foundation of the Academy of Athens, Departments of Genetics, Biology and Biochemistry, University of Turin, MD Anderson Cancer Center, The University of Texas Health Science Center at Houston (UTHealth), CIC BioGUNE, CIC Spain, Department of urology, The University of Texas M.D. Anderson Cancer Center [Houston], Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Università degli studi di Torino = University of Turin (UNITO)
Jazyk: angličtina
Rok vydání: 2014
Předmět:
Zdroj: Urologic Oncology: Seminars and Original Investigations
Urologic Oncology: Seminars and Original Investigations, Elsevier, 2014, 32 (7), pp.1061-1068. ⟨10.1016/j.urolonc.2013.10.010⟩
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Urologic Oncology: Seminars and Original Investigations, 2014, 32 (7), pp.1061-1068. ⟨10.1016/j.urolonc.2013.10.010⟩
ISSN: 1078-1439
DOI: 10.1016/j.urolonc.2013.10.010⟩
Popis: Objectives: Many molecular assays for bladder cancer diagnosis and surveillance have been developed over the past several decades. However, none of these markers have been routinely implemented into clinical decision making. Beyond their potential for screening high-risk populations, urine markers likely have the greatest potential in the follow-up of patients with non muscle invasive bladder cancer (NMIBC). Methods: Here, we discuss the current options and limitations of the use of urine markers for patient surveillance, focusing on patients with low-/intermediate-risk NMIBC. Results: As these patients have a very low risk of tumor progression, the primary goal of surveillance is detection of recurrent disease. Although urine cytology seems to be limited to detection of few patients who would develop high-grade tumors, we conclude that the use of markers with high sensitivity for low-grade disease for patient follow-up has the potential to decrease the frequency of urethrocystoscopy without compromising patient prognosis. Because a single marker may not have sufficient sensitivity for detection of low-grade tumors, different scenarios, e.g., multitesting and reflex or sequential approaches, are discussed. Conclusions: There is consensus that currently available markers have the potential to support clinical decision making in follow-up of patients with low-/intermediate-risk NMIBC. In light of our analysis, further additional randomized controlled studies to effectively assess the clinical usefulness of modem urine markers are required. (C) 2014 Elsevier Inc. All rights reserved.
Databáze: OpenAIRE
Externí odkaz: